Skip to main content
Reimbursement strategy

Cost-effective market access strategy for medical technologies in Europe

A holistic approach to reimbursement strategies trusted by global market leaders and SMEs

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

MTRC has released a White Paper highlighting the challenges of Health Economic Evaluations of Medical Devices

Health economic evaluations are essential for demonstrating the value of medical technologies to healthcare providers, payers, policy-makers and health technology assessment (HTA) bodies. However, medical devices present unique challenges in generating robust health economic evidence, particularly due to rapid innovation cycles, user-dependent outcomes, short follow-up periods, documenting assumptions, appropriate costing methods, and limited availability of high-quality data. 

Several commonly used methods of health economic evaluations of medical technologies include cost-consequence analysis, cost-effectiveness analysis, cost-utility analysis, and budget impact analysis.

In this White Paper, MTRC explores the challenges, highlights methodological nuances of various health economic evaluations, and offers best practices to help medical device companies develop health economic evidence for medical devices more effectively.

Read more and request a White Paper here.